Clinical trials
Trial 1 — University of Sydney / Australasian Research Institute (2018–2021)
"Improvements in Clinical Signs of Parkinson's Disease Using Photobiomodulation" Lead: Dr. Ann Liebert Registry: ACTRN12618000038291p (Australian New Zealand Clinical Trials Registry) This home-based photobiomodulation therapy trial recruited 12 participants with idiopathic PD and used the Well Red Duo Coronet as one of the transcranial devices. The trial demonstrated that home-based, self-applied PBM has the potential to complement standard therapies and manage symptoms.
PubMed 🔗 ANZCTR Registry
Trial 2 — NIIM Melbourne (ongoing)
Cognition and Photobiomodulation Trial, National Institute of Integrative Medicine, Melbourne.
The Well Red Duo Coronet is currently being used in a double-blind, randomised, sham-controlled feasibility clinical trial at the National Institute of Integrative Medicine (NIIM) in Melbourne, Australia to measure the effect of photobiomodulation with red light on cognitive function in adults with Alzheimer's or Parkinson's Disease. Trial ID ACTRN12625001392459
Well Red 🔗 NIIM Research Page
Trial 3 — Clinatec Institute, Grenoble, France (ongoing)
Intracranial + Transcranial PBM for Parkinson's Disease The Well Red Duo Coronet is being used in a double-blind, randomised, sham-controlled clinical trial at the Clinatec Institute in Grenoble, France, which is investigating both intracranial implants and transcranial light devices.
Well Red 🔗 Clinatec Clinical Trials
Trial 4 — University of Sydney (randomised feasibility study, 2023)
"A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study" Herkes G, McGee C, Liebert A, Bicknell B, et al. eClinicalMedicine (The Lancet) 2023 Dec;66:102338. doi:10.1016/j.eclinm.2023.102338 This was a double-blind, randomised, sham-controlled feasibility trial involving patients aged 59–85 with idiopathic Parkinson's disease. They were treated with the Well Red Duo Coronet transcranial PBM helmet for 12 weeks (72 treatments), delivered in participants' homes and monitored via Zoom.
PubMed 🔗 PubMed | Lancet eClinicalMedicine
Trial 5 — University of Lancashire, England, UK (starting)
Intracranial + Transcranial PBM for Parkinson's Disease The Well Red Duo Coronet is being used in clinical trials at the University of Lancashire in England, which is investigating the effect of the Well Red Duo Coronet transcranial light device. This is a double-blind, randomised, sham-controlled trial.
Well Red 🔗 UCLan Clinical Trials
Details about the Duo Coronet
-
The Duo Coronet is made from aluminium into which high-quality, high-efficiency bespoke individual LED lights are soldered and controlled through firmware in the micro-controller that is built into the frame.
-
Visible red 670nm and near infrared 810nm shone in sequence have been shown to have the best effect on the cells in the brain. The visible red 670nm is particularly important, as it is a wavelength used by cells to communicate with each other. Cells have the apparatus to both emit and receive faint light pulses, called biophotons. It is thought that 670nm biophotons are sent by healthy cells to ailing cells to assist ailing cells function better. 670nm biophotons are strongly associated with cell health, and the Duo Coronet taps into this pre-existing cellular medical system.
Near infrared 810nm has the best penetration profile, and gets deeper into the brain. It is still effective in stimulating the cells that the 670nm light cannot reach. Learn how red and near infrared lights work.
-
Following our easy instructions, you can ease the Duo Coronet arms to fit your individual head shape. This is a critical feature, as the range of head shapes and sizes is infinite. Being able to shape the Duo Coronet for your head is the other reason why it is comfortable to wear. Here’s a link to the video instructions for setting up and fitting the Duo Coronet.
-
People who have had a stroke or traumatic brain injury which affects speech respond much better if they have lights shone only on the left side of their head, which houses the main speech area. The Duo Coronet can be set to shine lights only on the left side. Or the right side for that matter.
There are other situations in which just using visible red 670nm on its own is more helpful than using two wavelengths in sequence. This includes people struggling with Chronic Fatigue/Myalgic Encephalitis, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington’s disease.
Children with autism, seizures, ADHD, anxiety and depression respond well to the Duo Coronet, but the light dose needs to be made much less powerful and run for a much shorter duration.
Contact us if you have questions about your situation and we will work with you to find the best approach.
-
Pause and Resume:
There are times when you will want to pause the Coronet session. Simply give the button in the centre – where the right spoke meets the central circle – a short press. View image.
To resume the Coronet session, give the button another short press.
Halve the light power:
The Pause and Resume button can also be used to reduce the intensity of both wavelengths to half power.
To do this, hold the button down for at least 4 seconds. This change will only last for the duration of the current session.
To return to normal intensity, repeat this operation or restart the session.
-
Click here for more information about the App.
-
The Duo Coronet is designed with eight arms, and it travels from us to you in a safe, flat package. We include the correct power plug for your country. We give you detailed instructions including a video showing how to set up and fit your Coronet.
View image of Coronet in shipping box -
-
US Food and Drug Administration
Because of its safety profile, and the use of LED lights, the Well Red Duo Coronet is classified as a general wellness device and is not subject to regulation under the FDA’s Federal Food, Drug and Cosmetic Act.
Power supply
The power supply provided meets safety standards IEC60601-1, TUV EN60601-1, ANSI/AAMI ES60601-1 (3.1 version), CAN/CSA-C22.2 no.60601-1:14 – Edition 3, EAC TP TC 004 approved.